Isopeptidase-Fluorogenic Assays

Transglutaminases are able to also cleave the isopeptide bond. This principle is used to provide easy to handle, robust and precise fluorogenic assays suitable for screening of compound libraries and drug development. Further, it reliably detects levels as low as 5% of the physiological amount of FXIIIa (0.05 IU/ml) in plasma (Oertel et al., Anal. Biochem. 2007, 367:152-8).

Mechanism: transglutaminase cleaves the isopeptide bond releasing the dark quencher (2,4-dinitrophenyl) linked to the cadaverine spacer. Subsequently, the increase of fluorescence results from the N-terminally attached fluorophore 2-aminobenzoyl (2-Abz).

Zedira offers two different modified peptides A101 and A102 and the related assay kits F001 and F002. The transglutaminase family members discriminate between the peptides as shown in the table.


Isopeptidase activity Assay A101 and A102

Isopeptidase acitivity assay A101 and A102 principle


Art. No.
Name
Quantity
Price
A101 FXIII-Assay Substance,
Abz-NE(CAD-DNP)EQVSPLTLLK-OH
10 mg
520 €
A102 TG2-Assay Substance,
Abz-APE(CAD-DNP)QEA-OH
10 mg
415 €
F001 FXIII-Assay Kit
Based on substrate A101
1 Kit
575 €
F002 Tissue Transglutaminase Assay Kit
Based on substrate A102
1 Kit
520 €

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • MEDICA

    13.11.2017 - 16.11.2017
    Düsseldorf, Germany

  • Gordon Research Conference on: Transglutaminases in Human Disease Processes

    16.06.2018 - 17.06.2018
    Les Diablerets, Switzerland